Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia

A. A. Budayr, R. A. Nissenson, Robert Klein, K. K. Pun, O. H. Clark, D. Diep, C. D. Arnaud, G. J. Strewler

Research output: Contribution to journalArticle

186 Citations (Scopus)

Abstract

Study Objective: To measure the serum levels of a newly described parathyroid hormone-like protein (PLP), which was isolated from malignant tumors associated with hypercalcemia, and determine whether PLP is a humoral factor in malignancy-associated hypercalcemia. Design: A cross-sectional study of serum levels of PLP using a newly developed radioimmunoassay. Setting: A university-affiliated Veterans Administration hospital in San Francisco, California, a University hospital in Hong Kong, and a private hospital in Danville, Pennsylvania. Patients: Patients with hypercalcemia (calcium >2.65 mmol/L) and a diagnosis of malignancy were studied. Control groups included normocalcemic patients with malignancy, patients with hyperparathyroidism, and normal subjects. Measurements and Main Results: Serum immunoreactive PLP (iPLP) levels in normal subjects were less than 2.5 pmol eq/L (10 pg/mL), and 68% of subjects had undetectable levels. The serum concentration of iPLP was normal in 15 of 16 hypercalcemic patients with hyperparathyroidism. Serum iPLP was increased (>2.5 pmol eq/L) in 36 of 65 (55%) patients with malignancy-associated hypercalcemia, with a mean value of 6.1 ± 0.9 pmol eq/L (24 pg/mL). In a subgroup of patients with solid tumors, serum iPLP was increased in 30 (71%) of 42 hypercalcemic patients, with a mean value of 6.5 ± 0.9 pmol eq/L. Serum iPLP was elevated in only 3 of 23 normocalcemic patients with cancer. In patients with solid malignancies (n = 59), levels of iPLP were positively correlated with the total serum calcium (r = 0.43, P

Original languageEnglish (US)
Pages (from-to)807-812
Number of pages6
JournalAnnals of Internal Medicine
Volume111
Issue number10
StatePublished - 1989
Externally publishedYes

Fingerprint

Parathyroid Hormone-Related Protein
Hypercalcemia
Serum
Neoplasms
Hyperparathyroidism
Calcium
Veterans Hospitals
United States Department of Veterans Affairs
Private Hospitals
San Francisco
Hong Kong
Radioimmunoassay
Cross-Sectional Studies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Budayr, A. A., Nissenson, R. A., Klein, R., Pun, K. K., Clark, O. H., Diep, D., ... Strewler, G. J. (1989). Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia. Annals of Internal Medicine, 111(10), 807-812.

Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia. / Budayr, A. A.; Nissenson, R. A.; Klein, Robert; Pun, K. K.; Clark, O. H.; Diep, D.; Arnaud, C. D.; Strewler, G. J.

In: Annals of Internal Medicine, Vol. 111, No. 10, 1989, p. 807-812.

Research output: Contribution to journalArticle

Budayr, AA, Nissenson, RA, Klein, R, Pun, KK, Clark, OH, Diep, D, Arnaud, CD & Strewler, GJ 1989, 'Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia', Annals of Internal Medicine, vol. 111, no. 10, pp. 807-812.
Budayr, A. A. ; Nissenson, R. A. ; Klein, Robert ; Pun, K. K. ; Clark, O. H. ; Diep, D. ; Arnaud, C. D. ; Strewler, G. J. / Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia. In: Annals of Internal Medicine. 1989 ; Vol. 111, No. 10. pp. 807-812.
@article{e5d38cc2791e43f49b0caf84d1b8fe57,
title = "Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia",
abstract = "Study Objective: To measure the serum levels of a newly described parathyroid hormone-like protein (PLP), which was isolated from malignant tumors associated with hypercalcemia, and determine whether PLP is a humoral factor in malignancy-associated hypercalcemia. Design: A cross-sectional study of serum levels of PLP using a newly developed radioimmunoassay. Setting: A university-affiliated Veterans Administration hospital in San Francisco, California, a University hospital in Hong Kong, and a private hospital in Danville, Pennsylvania. Patients: Patients with hypercalcemia (calcium >2.65 mmol/L) and a diagnosis of malignancy were studied. Control groups included normocalcemic patients with malignancy, patients with hyperparathyroidism, and normal subjects. Measurements and Main Results: Serum immunoreactive PLP (iPLP) levels in normal subjects were less than 2.5 pmol eq/L (10 pg/mL), and 68{\%} of subjects had undetectable levels. The serum concentration of iPLP was normal in 15 of 16 hypercalcemic patients with hyperparathyroidism. Serum iPLP was increased (>2.5 pmol eq/L) in 36 of 65 (55{\%}) patients with malignancy-associated hypercalcemia, with a mean value of 6.1 ± 0.9 pmol eq/L (24 pg/mL). In a subgroup of patients with solid tumors, serum iPLP was increased in 30 (71{\%}) of 42 hypercalcemic patients, with a mean value of 6.5 ± 0.9 pmol eq/L. Serum iPLP was elevated in only 3 of 23 normocalcemic patients with cancer. In patients with solid malignancies (n = 59), levels of iPLP were positively correlated with the total serum calcium (r = 0.43, P",
author = "Budayr, {A. A.} and Nissenson, {R. A.} and Robert Klein and Pun, {K. K.} and Clark, {O. H.} and D. Diep and Arnaud, {C. D.} and Strewler, {G. J.}",
year = "1989",
language = "English (US)",
volume = "111",
pages = "807--812",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "10",

}

TY - JOUR

T1 - Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia

AU - Budayr, A. A.

AU - Nissenson, R. A.

AU - Klein, Robert

AU - Pun, K. K.

AU - Clark, O. H.

AU - Diep, D.

AU - Arnaud, C. D.

AU - Strewler, G. J.

PY - 1989

Y1 - 1989

N2 - Study Objective: To measure the serum levels of a newly described parathyroid hormone-like protein (PLP), which was isolated from malignant tumors associated with hypercalcemia, and determine whether PLP is a humoral factor in malignancy-associated hypercalcemia. Design: A cross-sectional study of serum levels of PLP using a newly developed radioimmunoassay. Setting: A university-affiliated Veterans Administration hospital in San Francisco, California, a University hospital in Hong Kong, and a private hospital in Danville, Pennsylvania. Patients: Patients with hypercalcemia (calcium >2.65 mmol/L) and a diagnosis of malignancy were studied. Control groups included normocalcemic patients with malignancy, patients with hyperparathyroidism, and normal subjects. Measurements and Main Results: Serum immunoreactive PLP (iPLP) levels in normal subjects were less than 2.5 pmol eq/L (10 pg/mL), and 68% of subjects had undetectable levels. The serum concentration of iPLP was normal in 15 of 16 hypercalcemic patients with hyperparathyroidism. Serum iPLP was increased (>2.5 pmol eq/L) in 36 of 65 (55%) patients with malignancy-associated hypercalcemia, with a mean value of 6.1 ± 0.9 pmol eq/L (24 pg/mL). In a subgroup of patients with solid tumors, serum iPLP was increased in 30 (71%) of 42 hypercalcemic patients, with a mean value of 6.5 ± 0.9 pmol eq/L. Serum iPLP was elevated in only 3 of 23 normocalcemic patients with cancer. In patients with solid malignancies (n = 59), levels of iPLP were positively correlated with the total serum calcium (r = 0.43, P

AB - Study Objective: To measure the serum levels of a newly described parathyroid hormone-like protein (PLP), which was isolated from malignant tumors associated with hypercalcemia, and determine whether PLP is a humoral factor in malignancy-associated hypercalcemia. Design: A cross-sectional study of serum levels of PLP using a newly developed radioimmunoassay. Setting: A university-affiliated Veterans Administration hospital in San Francisco, California, a University hospital in Hong Kong, and a private hospital in Danville, Pennsylvania. Patients: Patients with hypercalcemia (calcium >2.65 mmol/L) and a diagnosis of malignancy were studied. Control groups included normocalcemic patients with malignancy, patients with hyperparathyroidism, and normal subjects. Measurements and Main Results: Serum immunoreactive PLP (iPLP) levels in normal subjects were less than 2.5 pmol eq/L (10 pg/mL), and 68% of subjects had undetectable levels. The serum concentration of iPLP was normal in 15 of 16 hypercalcemic patients with hyperparathyroidism. Serum iPLP was increased (>2.5 pmol eq/L) in 36 of 65 (55%) patients with malignancy-associated hypercalcemia, with a mean value of 6.1 ± 0.9 pmol eq/L (24 pg/mL). In a subgroup of patients with solid tumors, serum iPLP was increased in 30 (71%) of 42 hypercalcemic patients, with a mean value of 6.5 ± 0.9 pmol eq/L. Serum iPLP was elevated in only 3 of 23 normocalcemic patients with cancer. In patients with solid malignancies (n = 59), levels of iPLP were positively correlated with the total serum calcium (r = 0.43, P

UR - http://www.scopus.com/inward/record.url?scp=0024425375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024425375&partnerID=8YFLogxK

M3 - Article

C2 - 2817628

AN - SCOPUS:0024425375

VL - 111

SP - 807

EP - 812

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 10

ER -